

# COST EFFECTIVENESS WORKING GROUP MEETING

## ERS Conference 2018

### MINUTES

<b>Meeting location</b>	Mercure Parc des Expositions, 36 38 Rue du Moulin, 92170, Vanves, France	
<b>Meeting date</b>	Saturday 15 September 2018	
<b>Meeting time</b>	13:00 – 14:00	
<b>Chair</b>	Job van Boven	
<b>Attendees</b>	Richard Costello Dermot Ryan Leif Bjermer Joan Soriano Jaco Voorham Naomi Lauanders Kathryn Brown	Glenn Crater Sinthia Bosnic-Anticevich Ted Popov George Christoff Keith Allan Michael Walker
<b>Objective</b>	<ul style="list-style-type: none"> <li>Brainstorm new ideas for projects</li> <li>Determine plans for implementation and funding of these projects</li> </ul>	

1	<p><b>Plans for future projects</b></p> <ul style="list-style-type: none"> <li><b>The global economic burden of COPD in non-smokers</b></li> </ul> <p>This was discussed at length. Passive smoking (including exposure in utero) was discussed as a limitation to the definition of “non-smokers”. There may still be smoke exposure. It was suggested that before a cost analysis is done it may be necessary to look at if non-smokers with COPD are different and if so, how.</p> <p>The issue of under-diagnosis, misdiagnosis and poor recording was discussed. The difficulty of summarizing at a country level was also discussed, as there may be pockets of unusually high or low incidence.</p> <p>The Global Burden of Disease data was discussed as a first step. The 2017 data is coming out in November. Smoking data is going to be very approximate.</p> <p>It was raised that maybe the study team should look at the costs of all COPD and then split by smoking status.</p> <p>Action: Study team to clarify what the next steps should be.</p> <ul style="list-style-type: none"> <li><b>Other research ideas</b> <ul style="list-style-type: none"> <li><i>Cost-effectiveness analysis of REG COPD missed opportunities study:</i> It was felt similar projects may already be underway, in terms of case-finding in COPD.</li> </ul> </li> </ul>
---	---

	<ul style="list-style-type: none"> <li>○ <i>Emphasis on treatable traits in asthma and COPD management and the implications for economic evaluations and Economic consideration in precision medicine for COPD: It was felt that these two projects are very broad and may be the topic of a position paper rather than a study per se.</i></li> </ul>
3	<p><b>New project ideas/ AOB</b></p> <p>It was asked if there were any novel techniques that REG could be using and there was a discussion around artificial intelligence/machine learning and how these may alter the models. This would require an expert in this field. Job van Boven has a PhD student who is looking into this.</p> <p><b>Action:</b> REG to identify if they have any contacts with this expertise and liaise further with Job.</p> <p>The use of pharmacy prescribing data was discussed, and the possibility of looking for missed opportunities for diagnosis or characteristics in medicine use in the years prior to diagnosis. While this may not have a cost element, it was thought that comparing pharmacy prescriptions to GP prescriptions in e.g. the Northern Ireland database could be of interest to the adherence group.</p> <p>Action: Email adherence lead and Sinthia with potential idea.</p>